-
Article
Transdermal Delivery of Heparin Using Pulsed Current Iontophoresis
In clinical practice heparin has to be administered by injection with obvious disadvantages; thus, transdermal delivery by electrically assisted methods have been studied. In this study we evaluated the effica...
-
Article
Open AccessPreliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder
Among genitourinary malignancies, bladder cancer (BCa) ranks second in both prevalence and cause of death. Biomarkers of BCa for diagnosis, prognosis and disease surveillance could potentially help prevent pro...
-
Article
Expression array analysis of the hepatocyte growth factor invasive program
Signaling by human hepatocyte growth factor (hHGF) via its cell surface receptor (MET) drives mitogenesis, motogenesis and morphogenesis in a wide spectrum of target cell types and embryologic, developmental ...
-
Article
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
-
Article
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Trastuzumab has shown a survival benefit in cases of Her2-positive gastroesophageal cancer (GEC). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) currently determine eligibility for tr...
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
-
Article
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Hypoactive BRAF mutants bind more tightly than wild type to the upstream regulator RAS, thus amplifying to amplify ERK signalling; tumours expressing these mutants require coexistent mechanisms for RAS activat...
-
Article
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
The role of KRAS, when activated through canonical mutations, has been well established in cancer1. Here we explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene ...
-
Article
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
In the Supplementary Information originally published with this article, a lane was missing in the β-actin blot in Supplementary Fig. 2. The lane has been added. The error has been corrected in the Supplementa...
-
Article
Open AccessTargeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
Protein biomarkers are widely used in cancer diagnosis, prognosis, and prediction of treatment response. Here we introduce the use of targeted multiplex proteomics (TMP) as a tool to simultaneously measure a p...
-
Article
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival
Understanding the molecular landscape of glioblastoma (GBM) is increasingly important in the age of targeted therapy. O-6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation and EGFR amplification are...
-
Article
Open AccessCombination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
The vascular endothelial growth factor (VEGF)/VEGFR and hepatocyte growth factor (HGF)/c-MET signaling pathways act synergistically to promote angiogenesis. Studies indicate VEGF inhibition leads to increased ...
-
Article
Open AccessThe addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies
Mass spectrometry-based targeted proteomics allows objective protein quantitation of clinical biomarkers from a single section of formalin-fixed, paraffin-embedded (FFPE) tumor tissue biopsies. We combined hig...
-
Article
Open AccessHER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We...